Aurora Cannabis (ACB) Competitors

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, community ranking, media sentiment, risk and dividends.

Is AUPH or ACB more profitable?

Aurora Cannabis has a net margin of 0.42% compared to Aurinia Pharmaceuticals' net margin of -10.23%. Aurora Cannabis' return on equity of 0.59% beat Aurinia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	-10.23%	-4.41%	-3.07%
Aurora Cannabis	0.42%	0.59%	0.42%

Does the media prefer AUPH or ACB?

In the previous week, Aurinia Pharmaceuticals had 1 more articles in the media than Aurora Cannabis. MarketBeat recorded 5 mentions for Aurinia Pharmaceuticals and 4 mentions for Aurora Cannabis. Aurinia Pharmaceuticals' average media sentiment score of 1.76 beat Aurora Cannabis' score of 0.36 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Aurora Cannabis	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts rate AUPH or ACB?

Aurinia Pharmaceuticals currently has a consensus target price of $11.50, suggesting a potential upside of 41.10%. Given Aurinia Pharmaceuticals' higher probable upside, equities analysts plainly believe Aurinia Pharmaceuticals is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Aurora Cannabis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.67

Does the MarketBeat Community believe in AUPH or ACB?

Aurinia Pharmaceuticals received 193 more outperform votes than Aurora Cannabis when rated by MarketBeat users. Likewise, 73.41% of users gave Aurinia Pharmaceuticals an outperform vote while only 59.63% of users gave Aurora Cannabis an outperform vote.

Company	Underperform	Outperform
Aurinia Pharmaceuticals	Outperform Votes 577 73.41%	Underperform Votes 209 26.59%
Aurora Cannabis	Outperform Votes 384 59.63%	Underperform Votes 260 40.37%

Which has stronger valuation & earnings, AUPH or ACB?

Aurora Cannabis has higher revenue and earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$247.30M	4.45	-$78.02M	$0.28	29.11
Aurora Cannabis	$320.81M	1.04	-$48.62M	$0.05	119.00

Do institutionals and insiders believe in AUPH or ACB?

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are owned by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are owned by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Which has more volatility & risk, AUPH or ACB?

Aurinia Pharmaceuticals has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500.

Summary

Aurora Cannabis beats Aurinia Pharmaceuticals on 10 of the 19 factors compared between the two stocks.